Dermatology Times November 2025 Print Recap

The November issue of Dermatology Times includes a collection of thought-provoking articles and topics as we explore insights into collaborative care between dermatologists and allergists while treating patients with chronic spontaneous urticaria.

Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplement each month.

Cracking the Code of Chronic Spontaneous Urticaria: Evolving Care by Allergists and Dermatologists

When seeing a patient with suspected chronic spontaneous urticaria (CSU) for the first time, it has often been months or even years since their search for a diagnosis began. With a disease characterized by recurrent hives, angioedema, or both for more than 6 weeks without a known cause, the journey toward CSU diagnosis and relief is often fraught with frustration due to lack of consistent adherence with diagnostic and treatment guidelines and a relative lack of collaboration in decision-making between providers and patients. Based on the current landscape, it is increasingly important for allergists and dermatologists to align on an effective approach based on the best and latest evidence.

Read more from David M. Lang, MD, FAAAAI, FACAAI, FACP, and Naiem Issa, MD, PhD, FAAD

Psoriasis Care Evolves as Oral IL-23 Blockers Show Lasting Control

At the 2025 European Academy of Dermatology and Venereology Congress in Paris, France, oral therapies stole the spotlight—signaling what may be the most significant shift in psoriasis care since the advent of biologics. With phase 3 data now demonstrating that icotrokinra (Johnson & Johnson), an oral interleukin (IL)-23 receptor blocker, outperforms deucravacitinib (Sotyktu; Bristol Myers Squibb), enthusiasm is mounting among clinicians eager for effective, needle-free options. Yet amid the excitement, the field continues to weigh icotrokinra’s efficacy, durability, and safety against the practical realities of long-term, evidence-based dermatologic care.

Read more

Beyond Antibiotics: How Oral Denifanstat Could Reshape the Acne Pipeline

A potential game-changer in acne treatment is on the horizon. Denifanstat (ASC40), a first-in-class oral therapy developed by Ascletis Pharma Inc, is redefining how moderate to severe acne vulgaris could be managed, moving beyond the long-standing reliance on antimicrobials, hormones, and retinoids. By targeting a completely new biological pathway, this breakthrough therapy could usher in a new era of acne care. Phase 3 safety and efficacy results were unveiled at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, France.

Read more

JAK3 Inhibitor Ritlecitinib Links Molecular Change to Visible Regrowth

Long considered irreversible, scarring alopecias may not be as final as once believed. Emerging translational data from Emma Guttman-Yassky, MD, PhD, and colleagues at the Icahn School of Medicine at Mount Sinai, in collaboration with Pfizer, is reshaping how clinicians approach autoimmune hair loss disorders. Their recent studies with ritlecitinib, a selective JAK3/TEC family kinase inhibitor, reveal that inflammation—not fibrosis alone—drives disease activity in both scarring and nonscarring alopecia phenotypes. By dampening JAK3-mediated immune signaling early, ritlecitinib appears capable of reopening the window for hair regrowth and recovery once thought permanently closed.

Read more

Click here to view all articles in the November issue.